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Abstract
Objectives
Liver biopsies are the current gold standard in non-alcoholic steatohepatitis (NASH) diagno-
sis. Their invasive nature, however, still carries an increased risk for patients’ health. The
development of non-invasive diagnostic tools to differentiate between bland steatosis
(NAFL) and NASH remains crucial. The aim of this study is the evaluation of investigated
circulating microRNAs in combination with new targets in order to optimize the discrimina-
tion of NASH patients by non-invasive serum biomarkers.
Methods
Serum profiles of four microRNAs were evaluated in two cohorts consisting of 137 NAFLD
patients and 61 healthy controls. In a binary logistic regression model microRNAs of rele-
vance were detected. Correlation of microRNA appearance with known biomarkers like
ALT and CK18-Asp396 was evaluated. A simplified scoring model was developed, combin-
ing the levels of microRNA in circulation and CK18-Asp396 fragments. Receiver operating
characteristics were used to evaluate the potential of discriminating NASH.
Results
The new finding of our study is the different profile of circulating miR-21 in NASH patients
(p<0.0001). Also, it validates recently published results of miR-122 and miR-192 to be differ-
entially regulated in NAFL and NASH. Combined microRNA expression profiles with CK18-
Asp396 fragment level scoring model had a higher potential of NASH prediction compared
to other risk biomarkers (AUROC = 0.83, 95% CI = 0.754–0.908; p<0.001). Evaluation of
score model for NAFL (Score = 0) and NASH (Score = 4) had shown high rates of sensitivity
(91%) and specificity (83%).
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Conclusions
Our study defines candidates for a combined model of miRNAs and CK18-Asp396 levels
relevant as a promising expansion for diagnosis and in turn treatment of NASH.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in devel-
oped countries with a prevalence of 20 to 35% [1, 2]. Non-alcoholic fatty liver (NAFL) is
defined as bland steatosis and must be distinguished from non-alcoholic steatohepatitis
(NASH) which is characterized by inflammatory infiltrates, ballooning and necroapoptosis. 5%
to 20% of NAFLD patients develop a progression from NAFL to NASH. This is of particular
importance since the presence of NASH and/or advanced fibrosis has been associated with an
increased overall mortality in these patients [3, 4]. Liver biopsy with subsequent histological
examination still remains the gold standard in clinical practice to distinguish NAFL from
NASH. A common scoring system to differentiate between NAFL and NASH is the NAFLD
activity score (NAS) which is defined by the sum score of steatosis, ballooning, and lobular
inflammation [5].
For optimal follow-up and treatment of NAFLD patients, development of non-invasive
diagnostic tools to differentiate between NAFL and NASH remains crucial. In clinical practice,
clinical presentation including age, BMI, presence of type 2 diabetes and routine parameters
such as AST and ALT predict liver-related events [6–8]. Based on these observations the
NAFLD risk score has been developed [9]. Cytokeratin-18 (CK18-Asp396), an intermediary fil-
ament protein proteolytically cleaved by caspases during liver cell apoptosis [10, 11]. The resul-
tant CK18-Asp396 fragments have been investigated as a liver specific apoptosis and NASH
biomarker [12]. However, the sensitivity and positive predictive value for NASH is low [13]
and current practice guideline do not recommended CK18-Asp396 fragments as a single
marker for the detection of NASH [14]. Reliable serum biomarkers are still not available and
further promising candidates such as the interleukin 1 receptor antagonist (IL-1RA) have been
investigated in NASH patients [15].
Since microRNAs (miRNAs) have been discovered, scientists demonstrated a regulative
function in various gene expression pathways. MiRNAs are very stable in clinical samples as
they are resistant to the degradation by ribonucleases. This is one reason why circulating miR-
NAs have been proposed as attractive diagnostic tools for non-invasive assessment of a patho-
logical state of their origin organ/ tissue from peripheral blood [16]. The range of miRNA
applications is getting broader as they are used in different clinical settings for early disease
detection and monitoring of disease progression [17]. Very recently, Pirola et al. made an
attractive approach to improve the non-invasive assessment of NAFLD by using miRNAs as
potential diagnostic NASH markers [17].
Given the vast variability of miRNA results in different studies assessing the same disease
entity and important methodological differences between these studies [18–21], validation of
these results together with the evaluation of additional miRNA candidates is warranted. We
hypothesize that miRNAs in circulation as molecular marker of cell damage would indicate the
presence of NASH and contribute in combination to routine serum markers. The aim of this
study is to establish potential diagnostic miRNAs as biomarkers for the differentiation between
NAFL and NASH by defining a specific single or a grouped expression pattern for non-invasive
NASH diagnosis.
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Material and Methods
Study design, patients and healthy controls
A total of 137 NAFLD patients>18 years and 61 healthy controls (HC) were enrolled between
July 2007 and August 2014. NAFLD patients consisted of two different cohorts of patients, one
with a majority of moderate obesity from Hannover Medical School (MOC; n = 81; 16 NAFL/
65 NASH) and one with a majority of severely obese patients mostly undergoing bariatric sur-
gery fromWürzburg University Hospital (SOC; n = 56; 34 NAFL/ 22 NASH). Blood samples
were collected prior to any therapeutic procedure. Table 1 shows baseline parameters of the
Table 1. Baseline patient characteristics of study cohorts.
‘Severely obese cohort‘ (SOC)
Total: N = 99 (%) HC: N = 43 (43%) NAFL: N = 34 (34%) NASH: N = 22 (23%)
Sex, N (%): Male; Female 11 (26%); 32 (74%) 8 (24%); 26 (76%) 7 (32%); 15 (68%)
Age: Mean ± sd; Median (quartiles) 26.5 ± 3.2; 26 (21–37) 45.4 ± 10.6; 44.5 (22–64) 50.9 ± 10.8; 53 (30–77)
BMI: Mean ± sd; Median (quartiles) 21.4 ± 2.5; 21 (17.5–26.3) 49.4 ± 7.2; 49.7 (37.6–69.8) 48.7 ± 9.3; 47 (37–66.2)
Fasting glucose [mg/dl]:
Mean ± sd; Median (quartiles) n.d. 102 ± 24.5; 97 (71–178) 117.5 ± 51.5; 93.5 (71–244)
Triglycerides [mg/dl]: Mean ± sd; Median (quartiles) n.d. 166.7 ± 98.1; 143 (47–531) 188.2 ± 74.9; 162 (90–369)
Cholesterol total [mg/dl]: Mean ± sd; Median
(quartiles)
n.d. 197.7 ± 47.3;195 (114–307) 195.2 ± 28.7; 195 (128–258)
AST [U/l]: Mean ± sd; Median (quartiles) 20.4 ± 6.1; 19 (11.6–41.4) 30.8 ± 15.5; 25.5 (13.2–85.9) 45.9 ± 26.7; 36.3 (14–119
ALT [U/l]: Mean ± sd; Median (quartiles) 18.7 ± 8.0; 15.8 (10–46.6) 32.8 ± 18.2; 27 (13–179.4) 50.6 ± 20.3; 53.4 (19–89)
CK18-Asp396 [U/l]: Mean ± sd; Median (quartiles) 170.6 ± 54.8; 168 (91–
291)
235.8 ± 118.2; 218 (111–
646)
448.1 ± 252.4; 345 (139–996)
NAS: N = n.d./0/1-2/3/4; (%) 43/0/0/0/0; (100/0/0/0/0) 4/1/12/11/6; (12/3/35/32/18) 1/0/0/0/21; (5/0/0/0/95)
Fibroscan Elasticity [kPa]: Mean ± sd; Median
(quartiles)
4.3 ± 1.1; 4.1 (2.5–7.1) 9.3 ± 5.3; 8.1 (3.5–25.4) 13.1 ± 10.5; 10.4 (3.6–47.2)
Fibrosis: N = n.d./0/1/2/3/4; (%) 43/0/0/0/0/0; (100/0/0/0/0/
0)
6/15/11/0/0/2; (18/44/32/0/0/
6)
2/7/5/3/2/3; (9/32/22/14/9/14)
‘Moderate obese cohort‘ (MOC)
Total: N = 99 (%) HC: N = 18 (18%) NAFL: N = 16 (16%) NASH: N = 65 (66%)
Sex, N (%): Male; Female 6 (33%); 12 (67%) 12 (75%); 4 (25%) 39 (60%); 26 (40%)
Age: Mean ± sd; Median (quartiles) 33.4 ± 9.3; 31 (24–57) 45.3 ± 10.5; 46 (21–63) 47.2 ± 11.7; 48 (19–71)
BMI: Mean ± sd; Median (quartiles) n.d. 31.6 ± 6.3; 31 (25–48.1) 30.6 ± 4.1; 30 (25.2–45.9)
Fasting glucose [mmol/l]: Mean ± sd; Median
(quartiles)
n.d. 6.2 ± 1.8; 6 (4.6–10.7) 6.1 ± 1.5; 6 (3.9–9.6)
Triglycerides [mg/dl]: Mean ± sd; Median (quartiles) n.d. 157.2 ± 112.0; 108 (61–502) 189.9 ± 124.9; 151 (64–736)
Cholesterol total [mmol/l]: Mean ± sd; Median
(quartiles)
n.d. 209 ± 30.4; 206 (143–259) 222.1 ± 56.4; 213 (143–403)
AST [U/l]: Mean ± sd; Median (quartiles) n.d. 43.8 ± 19.0; 38 (23–96) 49.7 ± 20.7; 44 (16–116)
ALT [U/l]: Mean ± sd; Median (quartiles) n.d. 66.9 ± 43.5; 60 (26–176) 82.2 ± 47.0; 73 (13–221)
CK18-Asp396 [U/l]: Mean ± sd; Median (quartiles) 125.2 ± 25.3; 124 (85–
185)
183.8 ± 86.8; 149 (79–429) 380.7 ± 318.1; 260 (78–1897)
NAS: N = n.d./0/1-2/3/4; (%) 18/0/0/0/0; (100/0/0/0/0)) 0/0/16/0/0; (0/0/100/0/0) 0/0/0/17/48; (0/0/0/26/74)
Fibroscan Elasticity [kPa]: Mean ± sd; Median
(quartiles)
n.d. 5.7 ± 1.4; 5 (3.3–9.1) 8.2 ± 4.5; 7 (3.7–25.7)
Fibrosis: N = n.d./0/1/2/3/4; (%) 18/0/0/0/0/0; (100/0/0/0/0/
0)
2/8/6/0/0/0; (12/50/38/0/0/0) 3/21/26/10/4/1; (5/32/40/15/6/
2))
Results are expressed as mean ± standard deviation, as well as median (quartiles) unless indicated differently.
doi:10.1371/journal.pone.0142661.t001
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moderate obese and severely obese cohort as well as controls. Patients with significant alcohol
consumption (females> 20g/day and males> 30g/day) and any pre-existing liver disease were
excluded. Healthy control subjects seeking a routine health check-up at the Würzburg Univer-
sity Hospital or Hannover Medical School had no evidence or history of liver pathology, unre-
markable liver ultrasound, normal liver stiffness and no elevation of serum transaminases AST
and ALT. Furthermore, history of coronary heart disease, hypertension, valvular disease, any
arrhythmia or systemic disease resulted in exclusion of controls from the study.
Routine clinical and laboratory parameters were determined at baseline (age, BMI, fasting
glucose, triglyceride, total cholesterol, AST, ALT, CK18-Asp396) and liver stiffness was mea-
sured by transient elastography (Fibroscan1). For all patients, liver biopsies have been
obtained either percutaneously or during bariatric surgery (frustule size>20 mm; min.10 por-
tal tracts); histology has been evaluated by an experienced pathologist, who was blinded to the
results of Fibroscan and defined the presence of NASH and the NAS score [5]. The study was
approved by the Ethics Committee of Hannover Medical School, the Ethics Committee of
Würzburg University, and the Zürich Cantonal Ethics Committee. Written informed consent
was obtained from each participant and the entire study was conducted in accordance with the
declaration of Helsinki.
CK18-Asp396 measurement
The apoptosis-associated neoepitope CK18-Asp396 was measured by using the M30-Apopto-
sense ELISA according to the manufacturer's instructions (Peviva, Bromma, Sweden) and as
described previously [22].
Blood samples and RNA isolation
Small RNA fraction was extracted from 200 μL serum using the miRCURY TM RNA isolation
kit—Biofluids (Exiqon A/S, Denmark) according to the manufacturer's protocol (v1.4; April
2014) with three minor variations. Specifically, before starting with isolation, 1μg of MS2 RNA
from bacteriophage MS2 (Roche, Switzerland) was added to stabilize RNA during cDNA syn-
thesis. Additional, 20 mg glycogen, RNA grade (Thermo Scientific) was added to inert co-pre-
cipitant of nucleic acids. The Exiqon UniSP6 Spike-in-Kit was added to monitor the yield of
RNA isolation via quantitative real-time PCR (RT-q-PCR). RNA was eluted from spin columns
in 50 μL nuclease-free water.
cDNA-synthesis and RT-q-PCR
RNA (2 μL) was reverse transcribed in 20 μL reactions using the miRCURY LNA Universal-
RT miRNA PCR kit (Exiqon A/S). The cDNA was diluted 1:40 and amplified in 10 μL PCR
reactions using specific LNA primer sets and the ExiLENT SYBR Green Master Mix (Exiqon-
A/S). The amplification was carried out on a 7900HT real-time PCR instrument (Applied Bio-
systems). As control, RT-q-PCR for miR-425 [23, 24] and miR-103 [25–27] (as reference miR-
NAs/ global mean [28–30]), miR-16 (as a reference to avoid the bias of relevant hemolysis) [31,
32] and UniSp6 (as monitor of efficiency of reverse transcription as recommended by provid-
ing company Exiqon for cDNA transcription [28]) were performed to guarantee equal quality
standard.
Statistics
Statistical analyses were performed with SPSS (Version 22, IBM, NY) and graphs were created
with Prism5 (GraphPad Software, La Jolla, CA).
Performance of microRNAs as Combination Biomarker in NASH-Patients
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P-values< 0.05 were considered statistically significant (< 0.05, < 0.01, < 0.001,
< 0.0001). Quantitative data were expressed as mean ± standard deviation unless otherwise
indicated. For relative miRNA expression average expression of miR-103 and miR-425 was
considered for normalization; 2-Δ Ct–method was used. To compare miRNA expression,
Mann-Whitney U test was applied. For binary logistic regression with SPSS in combined group
(SOC and MOC) the origin of the sample was included as co-variable to correct for differences
between the subgroups. Correlation between variables was calculated using Spearman’s Rank
correlation test. Scoring of miRNA expression was performed by separating their expression in
the entire NAFLD group by median (S1 Table), giving a ‘0’ for lower and equal values (lower
risk) and a ‘1’ for higher values (higher risk), which was chosen to avoid bias regarding differ-
ent RNA concentrations. Sum scores were in a range between 0 and 3 (or 0 and 4 when includ-
ing CK18-Asp396 as a fourth parameter).
For characteristic factors in combined patient group (SOC and MOC), receiver operating
characteristic (ROC) curve was calculated and area under ROC (AUROC) was evaluated with
SPSS.
Correction for multiple testing was not applied, as the focus of the study was rather explor-
atory for the use of miRNAs as diagnostic biomarkers.
Results
Differential expression of circulating miRNAs
Four different miRNAs (miR-122, miR-192, miR-21, miR-223) which have been involved in
chronic inflammatory liver disease and particularly NAFLD [17, 19, 33, 34] were quantified in
patient sera. The evaluation of miR-122 in both cohorts showed significant expression profile
change between control group and simple steatosis group (p<0.0001) and a significant further
increase between NAFL and NASH (p<0.0001) (Fig 1). The difference between HC and NAFL
was significant in both cohorts (moderately obese (MOC) and severely obese (SOC) patients),
whereas the difference between NAFL and NASH was only significant in SOC (p = 0.0051). In
MOC, in spite of consistent direction of effects, statistical significance was not obtained (S1
and S2 Figs). For miR-192 the same pattern of detected miRNAs as for miR-122 has been
observed with a significant increase in NAFL and NASH compared to HC (Fig 1). Again, the
difference between NAFL and NASH was only significant in SOC (p = 0.0022) (S1 and S2
Figs). Although the absolute difference was small, a significant increase of miR-21 expression
was observed for the NASH group compared to both other groups (p<0.0001) and could be
detected for both cohorts in separate (Fig 1, S1 and S2 Figs) (p(SOC) = 0.0007; p(MOC) =
0.0075). No relevant change in miR-21 profile between controls and simple steatosis could be
observed in both cohorts. An increase of miR-223 expression profile in serum of NASH
patients compared to NAFL and HC was only detectable in the severely obese cohort
(p = 0.0338), but was absent in MOC (Fig 1, S1 and S2 Figs).
To compare miRNA profile level with histological scores, delta Ct measures were correlated
to the corresponding NAS. For three miRNAs 122, 192 and 21 a significant discrimination for
groups with NAS n.d. + 0–2, 3+4 and 5+ has been detected with an overall trend towards lower
delta Ct measures with increasing NAS (Fig 2).
Contribution of miRNA and baseline patient parameters to the presence
of NASH
In the following the statistical contribution of miRNA serum levels to the diagnosis of NASH
was investigated in relation to established baseline factors by applying binary logistic
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regression. Established predictive parameters such as age, sex and BMI were considered as can-
didate co-variables for adjustment if a significant difference between the groups was calculated.
However, none of those baseline parameters had a significant influence on the presence of
NASH in both cohorts combined and in separate (Table 2).
In the combined analysis of both cohorts the deviation in size between the subgroups was
taken into consideration for correct adjusting. After adjustment for origin the three miRNAs
122, 192 and 21 turned out to be highly significant co-variables in the logistic regression analy-
sis (OR 0.592/p = 0.001, OR 0.487/p = 0.002 and OR 0.309/p<0.0001, respectively) (Table 2).
In MOC patients, parameters of significant influence were miR-21 and the cellular apoptosis-
marker CK18-Asp396 (p 0.05). In SOC patients, the number of relevant parameters further
included miR-122 and miR-192, whereas CK18-Asp396 was not significant in this subgroup.
From these results, it appeared straightforward to combine expression of miRNA-122, -192
and -21 for further analysis with the aim of defining a combined score of individual miRNA
markers for non-invasive NASH diagnosis.
Fig 1. Relative detection profile of four investigated circulatingmicroRNAs. Pooled data from both study cohorts (SOC &MOC). Displayed microRNAs
show significant difference in detection between NASH patients and healthy controls. MicroRNAs -122 (A), -192 (B) and -21 (D) discriminate between bland
steatosis and NASH patients. For miR-223, this difference could only be detected in one cohort (SOC; S1 Fig). MicroRNA data is normalized with miR-103
and miR-425. (Displayed: Median + interquartiles-range; whiskers = quartiles).
doi:10.1371/journal.pone.0142661.g001
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OR is<1 despite of a higher expected risk, as it is calculated with Δ-Ct values which have an
inverse correlation to increasing miRNA counts.
Correlation of routine serum parameters and miRNA expression profiles
in circulation
In a next step detected miRNA profiles were correlated to available routine serum parameters
such as ALT and CK18-Asp396 fragments (Fig 3). As miR-122 and miR-192 showed a very
similar profile pattern in the different patient groups, their correlation was highly significant
(R = 0.83, p< 0.0001, Fig 3). Both had a significant and positive correlation with serum ALT
(miR-122: R = 0.53, p< 0.0001; miR-192: R = 0.45, p< 0.0001) (Fig 3). CK18-Asp396 fragment
levels increased with the development of bland steatosis and the progression to NASH (Fig 3,
S3 Fig). Again, a positive and significant correlation of CK18-Asp396 fragments to respective
miRNA levels has been observed (miR-122: R = 0.48, p< 0.0001; miR-192: R = 0.36, p<
0.0001) (Fig 3). For miR-21 a positive significant correlation could be shown to ALT level but
no correlation to CK18-Asp396 or other miRNAs could be determined (S1 Table). For miRs-
21, -122 and -192 profile levels were also correlated with single NAS parameters (degree of
steatosis, ballooning, lobular inflammation and fibrosis). A relevant correlation of all individual
miR levels could be detected in comparison to the degree of steatosis. Also, a significant corre-
lation of lobular inflammation to miR-21 and miR-122 could be found (S1 Table).
Diagnostic performance of routine serum parameters, CK18-Asp396
fragments and miRNA levels in circulation
As a final step, diagnostic performance of miR-122, -192 and -21 in a combination score com-
pared to routine parameters such as ALT and CK18-Asp396 fragments has been analyzed in
NAFLD patients.
A simplified scoring system has been developed dividing measured expression in both
patient groups by the median (applied cut-offs shown in S2 Table) and subsequently scoring a
Fig 2. Circulating MicroRNA profile in comparison to histological NAS score.MicroRNA detection profile is shown as delta Ct. Pooled patient groups
with NAS n.d.+ 0–2, 3+4 and 5+ could be significantly discriminated by lower delta Ct measures for miR-122 (A), miR-192 (B) and miR-21 (data not shown;
p = 0.025–0.0258).
doi:10.1371/journal.pone.0142661.g002
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lower or equal appearance with ‘0’ and a higher with ‘1’ finally summing up the results for all
three miRNAs to a total score from 0 to 3. Alternatively, a combination with CK18-Asp396
fragment levels was applied, scored by the same method as miRNA expression with a total
score from 0 to 4. To evaluate the diagnostic performance of this miRNA sum scoring, we per-
formed a multivariate ROC and AUROC and compared it to ALT and CK18-Asp396 frag-
ments alone (Fig 4).
Prediction with combined miRNA profiles showed an increase in AUROC compared to
ALT alone (AUROC = 0.77) with the same diagnostic performance as CK18-Asp396 fragments
(both AUROC = 0.81). Combination of these two predictors by applying a scoring system from
0–4 further increased the area under ROC by additional 0.02 (= ΔAUROC), to a value of 0.83
(Fig 4), which is showing a high sensitivity for the absence of steatohepatitis (score 0) and the
diagnosis of NASH (score 4) (S4 Fig).
Table 2. Binary logistic regression analysis.
SOC
OR Conﬁdence Interval (95%) p-value
Age 1.049 0.995–1.106 0.076
Gender 1.517 0.458–5.020 0.495
BMI 0.995 0.935–1.060 0.887
CK18-Asp396 1.001 0.999–1.002 0.421
miR-122 0.526 0.332–0.834 0.006 **
miR-192 0.416 0.216–0.801 0.009 **
miR-223 0.556 0.306–1.010 0.054
miR-21 0.313 0.148–0.660 0.002 **
MOC
OR Conﬁdence Interval (95%) p-value
Age 1.014 0.968–1.063 0.552
Gender 0.5 0.145–1.72 0.272
BMI 0.956 0.842–1.085 0.487
CK18-Asp396 1.008 1.001–1.014 0.021 *
miR-122 0.666 0.430–1.032 0.069
miR-192 0.584 0.299–1.143 0.117
miR-223 0.858 0.382–1.927 0.71
miR-21 0.302 0.112–0.814 0.018 *
SOC and MOC (adjusted for origin)
OR Conﬁdence Interval (95%) p-value
Age 1.03 0.995–1.066 0.093
Gender 0.863 0.374–1.992 0.73
BMI 0.988 0.933–1.046 0.674
CK18-Asp396 1.002 1.000–1.003 0.09
miR-122 0.592 0.434–0.808 0.001 ***
miR-192 0.487 0.308–0.770 0.002 **
miR-223 0.643 0.402–1.029 0.066
miR-21 0.309 0.170–0.561 0.000 ****
*: 0,01 < p  0,05
**: 0,001 < p  0,01
***: 0,0001 < p  0,001
****: p  0,0001
doi:10.1371/journal.pone.0142661.t002
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Fig 3. Correlation between different circulatingmicroRNA levels and other serum parameters.MiR-122 and miR-192 showed a very similar profile in
the different patient groups; their correlation was highly significant (A). Correlation was also analyzed in comparison to the routine serum parameters ALT and
CK18-Asp396. MicroRNAs -122, and -192 could be positively correlated with ALT and CK-18 (B, C, E, F). CK18-Asp396 fragment levels increased with the
development of bland steatosis and the progression to NASH (D). Detailed results are displayed in S1 Table. Correlation between variables was calculated
using Spearman’s Rank correlation test.
doi:10.1371/journal.pone.0142661.g003
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The test result variable(s): Predicted probability has at least one tie between the positive
actual state group and the negative actual state group. Null hypothesis: true area = 0.5.
Discussion
Major differences for NAFL and NASH in the risk of progression to end stage liver disease,
decompensation and HCC development necessitate a reliable non-invasive risk assessment in
Fig 4. Diagnostic performance of microRNA level in circulation was evaluated bymultivariate receiver operating characteristic (ROC) in patient
group. Predictive potential of ALT (A) (AUROC: 0.77 / CI 95%: 0.685–0.854 / p: <0.001) and CK18-Asp396 (B) (AUROC: 0.81 / CI 95%: 0.733–0.837 /
p: <0.001) was evaluated, represented by calculated area under ROC (AUROC). MiR-122, -192 and -21 in a combination score showed comparable results
with CK18-Asp396 discrimination (C) (AUROC: 0.81/ CI 95%: 0.725–0.888 / p: <0.001). The best characteristics could be observed by combining the score
with CK18-Asp396 fragment level (D) (AUROC: 0.83 / CI 95%: 0.754–0.908 / p: <0.001) to differentiate between NAFL and NASH.
doi:10.1371/journal.pone.0142661.g004
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routine clinical practice. Currently no valid method to differentiate between NAFL and NASH
is available except liver biopsy with histological diagnosis. Therefore, the search for suitable
serum biomarkers is pursued with high priority.
We hypothesize that circulating miRNA profiles hold great potential to predict the presence
of NASH as serum biomarkers. Candidate miRNAs included miR-122 and -192, which have
been identified by previous studies as to be associated with NAFL and NASH [17]. Additional
candidate miR-21, which has been shown to be associated with clinically diagnosed but not
biopsy proven NAFLD [33]. MiR-223 appeared as another potential biomarker for NAFLD
progression since it has been shown to be significantly up-regulated in liver tissue of NASH
patients (unpublished data) and has been shown to be differentially expressed in serum of
HBV positive HCC patients [35].
MiR-122 represents the most abundant microRNA in adult human liver (approx. 70% of
total miRNAs) and has been associated with de novo lipogenesis and lipid trafficking [36, 37].
A significant increase of miR-122 in the serum of NASH patients has been identified with posi-
tive correlation to the stages of inflammation and fibrosis [37]. Li et al. described an inhibitory
effect of miR-122 on the stellate cell activation and collagen deposition within the liver indicat-
ing a link between decreased miR-122 and fibrotic liver damage [38]. In line with these obser-
vations, a decreased expression of miR-122 has been observed in liver tissue of patients
suffering from NAFLD [39]. Recently, Pirola et al. had shown increased miR-122 serum levels
with the manifestation of NASH [17]. Several studies have observed the decreased miR-122
expression within the liver and its increase in serum in the pathophysiological context of severe
liver disease and documented a correlation between hepatocyte destruction and miR-122
export [40–42]. Recently published data also suggested that elevated levels of miR-122 in the
circulation play a crucial role in regulation of genes involved in endothelial damage, as for
instance the L- arginine transporter SLC7A1 [17, 43, 44].
For miR-192 comparable data are scarce. MiR-192 has been shown to share a pri-miRNA
with miR-194 and to play a crucial role in diabetic nephropathy [45]. They are known to be
upregulated by TGFβ1 [45], a key fibrogenic cytokine in hepatic stellate cells. Recent data by
Pirola et al. indicating an increased miR-192 in liver tissue and serum of NAFL and NASH
patients, further underline the role of this miRNA in different pathologies within the metabolic
syndrome [17]. The present study confirms these observations indicating a significant correla-
tion of miR-122 and miR-192 to the manifestation of NASH [17]. Most importantly, signifi-
cant differences for both miRNAs between NAFL and NASH patients could be confirmed and
render these two as biomarker candidates.
MiR-21 has been associated with several diseases before and it was also one of the first
described oncomirs [46]. MiR-21 has also been identified as a potential diagnostic marker of
viral hepatitis [47, 48]. As a new finding in our study we could show that circulating miR-21
level is significantly increased in patients suffering from NASH compared to HC and NAFL
patients. An altered level in undifferentiated NAFLD has been shown before [33]. MiR-21 has
also been found elevated in the context of liver fibrosis and could be correlated with higher
fibrosis stages [49]. Although we do not detect such a correlation for the entire study popula-
tion we assume the differences in miR-21 expression between the NASH and NAFL group may
be at least partially reflected by increased fibrosis scores and fibroscan elasticities. The present
data now indicate that miR-21 is further increased in inflammatory states of fatty liver disease
since both cohorts showed a significant increase in NASH. The findings are in line with ele-
vated miR-21 in HCV infected serum and hepatocytes [48, 50] which also point to a role as a
marker for necroinflammatory activation in the context of viral infection.
An upregulation of miR-21 could be detected in hepatocytes after unsaturated fatty acid
treatment which leads to a specific binding of miR-21 to PTENmRNA thereby initiating its
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degradation [51]. This particular study mechanistically explains decreased PTEN expression in
high-fat diet treated rats and NAFLD patients and suggests miR-21 also as a key factor for the
progression from NASH to HCC [51].
MiR-192 and -122 could be significantly correlated with CK18-Asp396 and ALT levels indi-
cating that these miRNAs are released from hepatocytes during pathophysiological states asso-
ciated with cell membrane impairment. Previous data indicate an increase of miR-122 in
serum with apoptosis of hepatocytes caused by inflammatory damage of the liver [52] and
explain the positive correlation with the apoptosis marker CK18-Asp396 fragment. A new find-
ing here is the correlation between ALT- and miR-21 serum level. It can be hypothesized, that
these miRNAs generally show an earlier increase than ALT in NASH patients, as is has been
shown for miR-122 in the context of viral, drug- and alcohol-related liver disease [53, 54]. This
hypothesis is strengthened by the fact, that 25% of our NASH patients with predictive miRNA/
CK18-Asp396 score showed no abnormities in routine ALT level. The correlation between
mir-122 and -192 is bringing up the question for a potential link in miRNA processing and
regulation.
Our data on those two microRNAS are validated by the findings in a similar cohort Pirola
et al. investigated earlier [17]. As the authors already investigated the potential of single miR-
122 to predict NASH [17], the aim of our study consisted in combining potential microRNA-
and other biomarkers to increase the diagnostic performance in the discrimination of NASH
from lower risk NAFL patients. Tan et al. published in 2014 a panel of miRNAs suitable for the
discrimination of NAFLD patients against healthy controls but found no difference for the dif-
ferent disease states of fatty liver disease [19]. Focus of this study was on the diagnosis of
NASH patients within the entire group of NAFLD patients. Following this aim, for logistic
regression and further analysis all NAFLD patients (NAFL plus NASH) were included. Results
of our logistic regression analysis brought us to the conclusion to further analyse miR-122,
-192, and -21 as potential biomarkers candidates. As CK18-Asp396 fragments has been exten-
sively investigated as a biomarker candidate [10, 11, 14], we used this marker as a reference
together with serum ALT levels. Defining the median as critical threshold to discriminate a
‘lower risk’ from a ‘higher risk’ group for every single biomarker candidate a composite score
with and without CK18-Asp396 inclusion has been developed. In contrast to previous studies
[17], we found CK18-Asp396 fragment levels to have a higher prediction potential compared
to ALT shown in ROC analysis. Our combined scoring model had the same diagnostic perfor-
mance in the discrimination of NASH CK18-Asp396 fragment serum levels. Combining the
3-miRNA profiles panel with CK18-Asp396 fragments could further improve the diagnostic
performance as shown in receiver operating characteristics.
The outcome of our study bears high potential for future improvement of clinical routine,
particularly for early disease. Our findings hold the potential to develop a reliable serum bio-
marker panel to identify patients “at risk” for NASH and thereby decrease the currently almost
universal need of liver biopsies with potential complications for NASH diagnosis. Significant
differences in miRNA serum levels, detectable by a decrease in Ct values, in different NAS
groups together with a gradual increase starting with the earliest NAS stages fuel the assump-
tion, that early detection and in turn treatment could be optimized with the potential use of
miRNAs as candidate biomarkers.
Supporting Information
S1 Fig. Relative detection profile of four investigated circulating microRNAs in severely
obese cohort (SOC). Selected circulating microRNAs show significant difference in detection
between NASH and NAFL patients as well as NASH patients and healthy controls, respectively.
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MicroRNA data is normalized with miR-103 and miR-425. (Displayed: Mean + SEM).
(EPS)
S2 Fig. Relative detection profile of four investigated circulating microRNAs in moderate
obese cohort (MOC). Significant difference between NAFL and NASH patients could be
detected for miR-21. For microRNAs 122 and 192 a discrimination between NAFLD and
healthy controls was shown, whereas a significant difference between the different stages of
NAFLD could not be detected. MicroRNA data is normalized with miR-103 and miR-425.
(Displayed: Mean + SEM).
(EPS)
S3 Fig. Relative CK18-Asp396 fragment levels in moderate and severely obese cohort. In
independent cohorts an increased abundance could be detected with the development of bland
steatosis without further increase in NASH. (Displayed: Mean + SEM).
(EPS)
S4 Fig. Total number of patients scored with combined circulating microRNA
/CK18-Asp396 fragment level model. The majority of definite biopsy proven diagnosis for
NAFL and NASH are detected by scores 0 and 4 (sensitivity 91% and specificity 83%).
(PDF)
S1 Table. Correlation analysis with microRNA serum level.MicroRNA level in circulation
correlated with routine serum parameters ALT and CK18-Asp396 and with single NAS param-
eters (Steatosis, lobular inflammation, ballooning and fibrosis). Also miRNAs 122 and 192
have been correlated. Analysis is applied by Spearman’s rank correlation test.
(PDF)
S2 Table. Applied cut-offs for scoring model in both cohorts for miRNAs and
CK18-Asp396 fragment level. Scoring of miRNA profile was performed by separating their
expression in the entire NAFLD group by median, scoring ‘0’ for lower or equal values (lower
risk) and ‘1’ for higher values (higher risk).
(PDF)
Author Contributions
Conceived and designed the experiments: AG JS PPB. Performed the experiments: PPB JS.
Analyzed the data: PPB AG CH CM. Contributed reagents/materials/analysis tools: AGMR
HB CM CH BM.Wrote the paper: PPB AG.
References
1. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Current
pharmaceutical design. 2013; 19(29):5169–76. Epub 2013/02/12. PMID: 23394091.
2. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical
presentation and treatment. Digestive diseases (Basel, Switzerland). 2012; 30(2):158–62. Epub 2012/
06/23. doi: 10.1159/000336669 PMID: 22722431.
3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-
up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865–73. doi: 10.1002/
hep.21327 PMID: 17006923.
4. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis pro-
gression in non-alcoholic steatohepatitis. Journal of hepatology. 2009; 51(2):371–9. Epub 2009/06/09.
doi: 10.1016/j.jhep.2009.03.019 PMID: 19501928.
5. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. Nonalcoholic fatty
liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct
Performance of microRNAs as Combination Biomarker in NASH-Patients
PLOS ONE | DOI:10.1371/journal.pone.0142661 November 13, 2015 13 / 16
clinicopathologic meanings. Hepatology. 2011; 53(3):810–20. doi: 10.1002/hep.24127 PMID:
21319198; PubMed Central PMCID: PMC3079483.
6. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonal-
coholic steatohepatitis. Hepatology. 1999; 30(6):1356–62. Epub 1999/11/26. doi: 10.1002/hep.
510300604 PMID: 10573511.
7. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight
patients. Gastroenterology. 2000; 118(6):1117–23. Epub 2000/06/02. PMID: 10833486.
8. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a
simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57
(10):1441–7. Epub 2008/04/09. doi: 10.1136/gut.2007.146019 PMID: 18390575.
9. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple non-
invasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastro-
enterology. 2013; 145(4):782–9.e4. Epub 2013/07/19. doi: 10.1053/j.gastro.2013.06.057 PMID:
23860502; PubMed Central PMCID: PMCPmc3931256.
10. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermedi-
ate filaments during epithelial cell apoptosis. The Journal of cell biology. 1997; 138(6):1379–94. Epub
1997/09/23. PMID: 9298992; PubMed Central PMCID: PMCPmc2132555.
11. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early
apoptosis in liver diseases. European journal of cell biology. 2001; 80(3):230–9. Epub 2001/04/27. doi:
10.1078/0171-9335-00154 PMID: 11322387.
12. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic bio-
marker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obesity surgery. 2008; 18
(11):1430–7. Epub 2008/05/27. doi: 10.1007/s11695-008-9506-y PMID: 18500507.
13. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-
18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of
hepatology. 2014; 60(1):167–74. Epub 2013/08/27. doi: 10.1016/j.jhep.2013.07.042 PMID: 23973932.
14. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and manage-
ment of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study
of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Asso-
ciation. Hepatology. 2012; 55(6):2005–23. doi: 10.1002/hep.25762 PMID: 22488764.
15. Pihlajamaki J, Kuulasmaa T, Kaminska D, Simonen M, Karja V, Gronlund S, et al. Serum interleukin 1
receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. Journal of
hepatology. 2012; 56(3):663–70. Epub 2011/10/27. doi: 10.1016/j.jhep.2011.10.005 PMID: 22027586.
16. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as bio-
markers for human diseases. RNA biology. 2012; 9(6):850–9. Epub 2012/06/16. doi: 10.4161/rna.
20378 PMID: 22699556.
17. Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez
LedesmaM, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-
coding RNAs to liver histology and disease pathogenesis. Gut. 2014. doi: 10.1136/gutjnl-2014-306996
PMID: 24973316; PubMed Central PMCID: PMC4277726.
18. Sobolewski C, Calo N, Portius D, Foti M. MicroRNAs in Fatty Liver Disease. Seminars in liver disease.
2015; 35(1):12–25. doi: 10.1055/s-0034-1397345 PMID: 25632931.
19. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serummicroRNAs panel as potential biomarkers for
diagnosis of nonalcoholic fatty liver disease. PloS one. 2014; 9(8):e105192. doi: 10.1371/journal.pone.
0105192 PMID: 25141008; PubMed Central PMCID: PMC4139327.
20. Haider BA, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK. A critical evaluation of micro-
RNA biomarkers in non-neoplastic disease. PloS one. 2014; 9(2):e89565. doi: 10.1371/journal.pone.
0089565 PMID: 24586876; PubMed Central PMCID: PMC3935874.
21. Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: Emerging Biomarkers of Liver Disease.
Seminars in liver disease. 2015; 35(1):43–54. Epub 2015/01/31. doi: 10.1055/s-0034-1397348 PMID:
25632934.
22. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apo-
ptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver
injury. Hepatology. 2004; 40(5):1078–87. doi: 10.1002/hep.20411 PMID: 15486927.
23. Bye A, Rosjo H, Aspenes ST, Condorelli G, Omland T, Wisloff U. Circulating microRNAs and aerobic fit-
ness—the HUNT-Study. PloS one. 2013; 8(2):e57496. Epub 2013/03/08. doi: 10.1371/journal.pone.
0057496 PMID: 23469005; PubMed Central PMCID: PMCPMC3585333.
24. Wang X, Sundquist J, Zoller B, Memon AA, Palmer K, Sundquist K, et al. Determination of 14 circulating
microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PloS one. 2014; 9(1):
Performance of microRNAs as Combination Biomarker in NASH-Patients
PLOS ONE | DOI:10.1371/journal.pone.0142661 November 13, 2015 14 / 16
e86792. Epub 2014/02/06. doi: 10.1371/journal.pone.0086792 PMID: 24497980; PubMed Central
PMCID: PMCPMC3907562.
25. Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: a 'nor-
mal' way to a hidden layer of complexity? Biotechnology letters. 2010; 32(12):1777–88. Epub 2010/08/
13. doi: 10.1007/s10529-010-0380-z PMID: 20703800.
26. Wang Y, Tang N, Hui T, Wang S, Zeng X, Li H, et al. Identification of endogenous reference genes for
RT-qPCR analysis of plasmamicroRNAs levels in rats with acetaminophen-induced hepatotoxicity.
Journal of applied toxicology: JAT. 2013; 33(11):1330–6. doi: 10.1002/jat.2864 PMID: 23558424.
27. Song J, Bai Z, HanW, Zhang J, Meng H, Bi J, et al. Identification of suitable reference genes for qPCR
analysis of serummicroRNA in gastric cancer patients. Digestive diseases and sciences. 2012; 57
(4):897–904. doi: 10.1007/s10620-011-1981-7 PMID: 22198701.
28. Exiqon-A/S. miRCURY LNA™Universal RT microRNA PCR—MicroRNA profiling in blood serum and
plasma. www.exiqon.com. 2014.
29. Mestdagh P, Derveaux S, Vandesompele J. Whole-genome RT-qPCRmicroRNA expression profiling.
Methods in molecular biology. 2012; 815:121–30. doi: 10.1007/978-1-61779-424-7_10 PMID:
22130988.
30. Mestdagh P, Van Vlierberghe P, DeWeer A, Muth D, Westermann F, Speleman F, et al. A novel and
universal method for microRNA RT-qPCR data normalization. Genome biology. 2009; 10(6):R64. Epub
2009/06/18. doi: 10.1186/gb-2009-10-6-r64 PMID: 19531210; PubMed Central PMCID:
PMCPMC2718498.
31. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, et al. Haemolysis dur-
ing sample preparation alters microRNA content of plasma. PloS one. 2011; 6(9):e24145. Epub 2011/
09/13. doi: 10.1371/journal.pone.0024145 PMID: 21909417; PubMed Central PMCID:
PMCPMC3164711.
32. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G. The Impact of Hemolysis on
Cell-Free microRNA Biomarkers. Frontiers in genetics. 2013; 4:94. Epub 2013/06/08. doi: 10.3389/
fgene.2013.00094 PMID: 23745127; PubMed Central PMCID: PMCPMC3663194.
33. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating
microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clinica chimica
acta; international journal of clinical chemistry. 2013; 424:99–103. doi: 10.1016/j.cca.2013.05.021
PMID: 23727030.
34. Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and
prognostic tools during the transition from steatosis to hepatocarcinoma. BioMed research interna-
tional. 2014; 2014:741465. Epub 2014/04/20. doi: 10.1155/2014/741465 PMID: 24745023; PubMed
Central PMCID: PMCPmc3972908.
35. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, et al. Profiles of serummicroRNAs;
miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
Molecular biology reports. 2014; 41(7):4513–9. doi: 10.1007/s11033-014-3322-3 PMID: 24595450.
36. Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, et al. Significance of serum and hepatic
microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver international: official journal
of the International Association for the Study of the Liver. 2014; 34(7):e302–7. Epub 2013/12/10. doi:
10.1111/liv.12429 PMID: 24313922.
37. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with
chronic hepatitis C and non-alcoholic fatty liver disease. PloS one. 2011; 6(8):e23937. doi: 10.1371/
journal.pone.0023937 PMID: 21886843; PubMed Central PMCID: PMC3160337.
38. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. miR-122 regulates collagen production via targeting
hepatic stellate cells and suppressing P4HA1 expression. Journal of hepatology. 2013; 58(3):522–8.
Epub 2012/11/28. doi: 10.1016/j.jhep.2012.11.011 PMID: 23178710; PubMed Central PMCID:
PMCPmc3619187.
39. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is
associated with altered hepatic MicroRNA expression. Hepatology. 2008; 48(6):1810–20. doi: 10.1002/
hep.22569 PMID: 19030170; PubMed Central PMCID: PMC2717729.
40. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in
liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.
Oncogene. 2009; 28(40):3526–36. Epub 2009/07/21. doi: 10.1038/onc.2009.211 PMID: 19617899;
PubMed Central PMCID: PMCPmc3492882.
41. Choi Y, Dienes HP, Krawczynski K. Kinetics of miR-122 expression in the liver during acute HCV infec-
tion. PloS one. 2013; 8(10):e76501. Epub 2013/10/15. doi: 10.1371/journal.pone.0076501 PMID:
24124569; PubMed Central PMCID: PMCPmc3790687.
Performance of microRNAs as Combination Biomarker in NASH-Patients
PLOS ONE | DOI:10.1371/journal.pone.0142661 November 13, 2015 15 / 16
42. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential bio-
markers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United
States of America. 2009; 106(11):4402–7. Epub 2009/02/28. doi: 10.1073/pnas.0813371106 PMID:
19246379; PubMed Central PMCID: PMCPmc2657429.
43. Pirola CJ, Gianotti TF, Castano GO, Sookoian S. Circulating MicroRNA-122 signature in nonalcoholic
fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome. Hepa-
tology. 2013; 57(6):2545–7. doi: 10.1002/hep.26116 PMID: 23111985.
44. Yang Z, Venardos K, Jones E, Morris BJ, Chin-Dusting J, Kaye DM. Identification of a novel polymor-
phism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endo-
thelial dysfunction. Circulation. 2007; 115(10):1269–74. Epub 2007/02/28. doi: 10.1161/circulationaha.
106.665836 PMID: 17325243.
45. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al. MicroRNA-192 in diabetic kidney glomer-
uli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Pro-
ceedings of the National Academy of Sciences of the United States of America. 2007; 104(9):3432–7.
Epub 2007/03/16. doi: 10.1073/pnas.0611192104 PMID: 17360662; PubMed Central PMCID:
PMCPmc1805579.
46. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, et al. MicroRNA-21 targets
tumor suppressor genes ANP32A and SMARCA4. Oncogene. 2011; 30(26):2975–85. Epub 2011/02/
15. doi: 10.1038/onc.2011.15 PMID: 21317927; PubMed Central PMCID: PMCPmc3134876.
47. Liu WH, Yeh SH, Chen PJ. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochi-
mica et biophysica acta. 2011; 1809(11–12):678–85. Epub 2011/05/14. doi: 10.1016/j.bbagrm.2011.
04.008 PMID: 21565290.
48. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, et al. SerummicroRNA-
21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma.
PloS one. 2011; 6(10):e26971. Epub 2011/11/09. doi: 10.1371/journal.pone.0026971 PMID:
22066022; PubMed Central PMCID: PMCPmc3205002.
49. Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, et al. miR-21 Inhibition Reduces Liver Fibrosis and
Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer research.
2015; 75(9):1859–67. Epub 2015/03/15. doi: 10.1158/0008-5472.can-14-1254 PMID: 25769721.
50. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S, et al. HCV-induced miR-21 contributes to evasion of host
immune system by targeting MyD88 and IRAK1. PLoS Pathog. 2013; 9(4):e1003248. Epub 2013/05/
02. doi: 10.1371/journal.ppat.1003248 PMID: 23633945; PubMed Central PMCID: PMCPMC3635988.
51. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids
inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21
up-regulation in hepatocytes. Hepatology. 2009; 49(4):1176–84. Epub 2008/12/17. doi: 10.1002/hep.
22737 PMID: 19072831.
52. Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, Vucur M, et al. Elevated miR-122
serum levels are an independent marker of liver injury in inflammatory diseases. Liver international: offi-
cial journal of the International Association for the Study of the Liver. 2015; 35(4):1172–84. Epub 2014/
07/22. doi: 10.1111/liv.12627 PMID: 25039534.
53. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, et al. PlasmamicroRNA-122 as a biomarker for viral-
, alcohol-, and chemical-related hepatic diseases. Clinical chemistry. 2010; 56(12):1830–8. Epub 2010/
10/12. doi: 10.1373/clinchem.2010.147850 PMID: 20930130.
54. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes
indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases.
Hepatology. 2012; 56(5):1946–57. doi: 10.1002/hep.25873 PMID: 22684891; PubMed Central PMCID:
PMC3486954.
Performance of microRNAs as Combination Biomarker in NASH-Patients
PLOS ONE | DOI:10.1371/journal.pone.0142661 November 13, 2015 16 / 16
